Arcturus Therapeutics Holdings (ARCT) EBITDA (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly EBITDA came in at -$28.9 million in Q1 2026, down 71.94% YoY from -$103.1 million in Q1 2025, and up 7.59% on a QoQ basis from -$31.3 million in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) EBITDA (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of EBITDA data on file, last reported at -$28.9 million in Q1 2026.
- Quarterly EBITDA fell 71.94% year-over-year to -$28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$88.4 million (down 7.65% YoY) and the FY2025 annual result came in at -$76.3 million, up 20.29% from the prior year.
- EBITDA advanced to -$28.9 million in Q1 2026, from -$31.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $121.5 million in Q4 2022 to a low of -$55.4 million in Q2 2023.
- A 5-year average of -$15.7 million and a median of -$21.1 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA jumped 422.62% — and 2024, when it tumbled 306.11%.
- Tracing ARCT's EBITDA over 5 years: stood at $121.5 million in 2022, then tumbled by 115.04% to -$18.3 million in 2023, then tumbled by 82.76% to -$33.4 million in 2024, then grew by 6.25% to -$31.3 million in 2025, then gained by 7.59% to -$28.9 million in 2026.
- The last three EBITDA figures came in at -$28.9 million (Q1 2026), -$31.3 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Arcturus Therapeutics Holdings | 233.92 Mn | 42.44 Mn | - | -25.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.55 Mn |
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -31.31 Mn |
| Sep 30, 2025 | -16.51 Mn |
| Jun 30, 2025 | -11.62 Mn |
| Mar 31, 2025 | -16.83 Mn |
| Dec 31, 2024 | -33.39 Mn |
| Sep 30, 2024 | -10.74 Mn |
| Jun 30, 2024 | -21.13 Mn |
| Mar 31, 2024 | -30.41 Mn |
| Dec 31, 2023 | -18.27 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -55.37 Mn |
| Mar 31, 2023 | 14.76 Mn |
| Dec 31, 2022 | 121.45 Mn |
| Sep 30, 2022 | -36.81 Mn |
| Jun 30, 2022 | -22.09 Mn |
| Mar 31, 2022 | -50.38 Mn |
| Dec 31, 2021 | -37.65 Mn |
| Sep 30, 2021 | -53.82 Mn |